Aconiazide, a hydrazone derivative of isoniazid, has been proposed for the treatment of tuberculosis. The toxicity of aconiazide was assessed by treating male and female Fischer 344 (F344) rats daily by gavage for 6 months at doses up to 400 mg/kg body wt. For comparison, the toxicity of isoniazid was determined following treatment in an identical manner at equimolar doses. Aconiazide resulted in only one death during the 6-month experiment, whereas isoniazid caused a significant increase in morbidity and mortality. Each drug induced significant dose-related decreases in body weight in both sexes, and isoniazid caused a significant decrease in liver weight in male rats. Isoniazid also induced centrilobular hepatic necrosis in male rats, a lesion not observed upon aconiazide treatment. Plasma drug levels were >lO-fold greater in rats administered isoniazid as compared to aconiazide. The higher levels of free drug observed with isoniazid may contribute to greater toxicity of isoniazid compared to aconiazide.
Tuberculosis continues to be a major health problem worldwide. In developing countries, it still accounts for 25% of the avoidable deaths in adults (Murray et al., 1990) , whereas in developed countries its incidence has increased due to the human immunodeficiency virus epidemic (Barnes et al., 1991; Bloom, 1992; Snider and Roper, 1992 ). An important drug for the treatment of tuberculosis is the isonicotinyl hydrazide, isoniazid ( Fig. I) (Bernstein et al., 1952; Fox, 1952; Pansy et al., 1952) . Although effective and widely used (Davidson and Le, 1992) , isoniazid can have severe side effects, the most common being hepatotoxicity (Garibaldi et al., 1972; Alford, 1990; AHFS, 1990; Davidson and Le, 1992) . Other adverse effects include a peripheral neuropathy , with possible degeneration of For each compound, 80 rats per sex were randomly allocated to four dosage groups, with 20 animals per sex per dose group. Individual animals were identified by the presence or absence of a left ear clip. The dosage groups consisted of a vehicle control (water), aconiazide at 100,200, or 400 mg/kg body wt of aconiazide (free acid; 0.33, 0.67, or 1.33 mmol, respectively), and isoniazid at 46, 91, or 183 mg/kg body wt (0.33, 0.67, or 1.33 mmol, respectively). Dosing solutions were prepared weekly. The aconiazide solutions were adjusted to pH 7.0-7.2. Due to logistical constraints, the aconiazide and isoniazid experiments were conducted sequentially. Separate control groups were used in each study. Aconiazide was dissolved at a concentration of 75 mg/ml, isoniazid at 35 mg/ml, and the treatment volumes were <2.6 ml for male rats and <1.3 ml for female rats. The rats were dosed 182 consecutive days by gavage, using INLIFE dosing software and a Micromedic Digiflex automated pipette. The overall efficiency of the drug delivery system was 99%.
With both drugs, 14 rats of each sex per dose level were designated for establishing the effects of aconiazide or isoniazid on liver and body weights, pathology, and hematological and clinical chemistry parameters. The remaining six rats of each sex per dose group for each drug were designated for establishing the plasma levels of aconiazide and/or isoniazid.
Necropsy and Histopathology
All surviving animals were fasted overnight after the last treatment on day 182. On day 183, these rats were weighed, anesthetized by exposure to C02, bled from the retro-orbital sinus, and killed by C02 euthanasia. All rats designated for pathology, including those that died or were removed before the end of the study, were examined grossly at necropsy and then microscopically. The sciatic and optic nerves, liver, and bone marrow were examined microscopically from all animals. Approximately 38 additional tissues were examined from the high-dose groups of both drugs and the concurrent control dose groups. Tissues were fixed in 10% buffered neutral formalin, processed, embedded, sectioned, and stained with hematoxylin and eosin for microscopic examination. Selected specimens of liver were stained with labeled antibody to proliferating cell nuclear antigen (PCNA; monoclonal antibody, clone PCIO; Dako Corp., Carpinteria, CA, U.S.A.) to distinguish proliferating hepatocytes.
Clinical Chemistry
Hematological measurements included erythrocyte, leukocyte, and platelet counts, hemoglobin, hematocrit, mean erythrocyte volume, mean erythrocyte hemoglobin, mean erythrocyte hemoglobin content, prothrombin time, partial thromboplastin time, and a leukocyte differential including reticulocytes and nucleated erythrocytes. Clinical chemistry serum analyses were conducted with a Baker Encore I1 and included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, creatinine, total protein, glucose, cholesterol, triglyceride, bilirubin, albumin, calcium, and phosphorous. Serum sodium and potassium analyses were conducted with a Corning 150 flame photometer.
Plasma Levels of Aconiazide and Isoniazid
One hour after dosing on days 15, 29, 43, 71, 99, 127, and 155 , each of the rats designated for the determination of aconiazide and/or isoniazid plasma levels was anesthetized by exposure to CO, and blood was collected from the retro-orbital sinus into test tubes containing ethylenediaminetetraacetic acid. Plasma was immediately prepared and stored frozen at -70°C.
The concentrations of aconiazide in plasma were assayed as previously described . Isoniazid plasma levels were assessed by vigorously mixing 250-pl aliquots of plasma with 150 p.1 of 10% zinc sulfate (w/v) and centrifuging at 2000 rpm for 10 min. Aliquots (250 kl) of the clear supernatants were transferred to new tubes, and 100 p.1 of methanol was added. The samples were mixed, centrifuged, and 5-p.1 aliquots were injected directly into an HPLC equipped with a ESA model 5100 A coulochem electrochemical detector and a model 501 1 analytical cell. The first cell was adjusted to + 0.6 V, and the detection cell was set to +0.8 V. Separations were conducted with a 250 x 4.6 mm (i.d.), 5-p. cyanopropyl bonded phase column (Supelco, Bellefonte, PA, U.S.A.), using a mobile phase of 95% water and 5% isopropanol that contained 0.5% ammonium formate. The flow rate was 1.0 mumin. Samples were quantified through comparison to an isoniazid standard solution.
Statistical Analyses
Fisher's Exact test for one-sided comparisons was used to determine differences in animal survival between control and treated animals. A two-sided version of the same test was performed to compare survival between rats administered aconiazide and isoniazid.
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A generalized growth curve multivariate model (Kleinbaum, 1973) was used to compare mean body weight differences across dose and time. In addition, Dunnett's method for multiple comparisons to control was performed to test for dose to control differences within the 26 weeks of dosing.
A one-way analysis of variance, with the use of contrasts (Winer, 1971) , was conducted to compare liver weights from the different doses. The p values were adjusted using a Bonferroni correction called Holm's procedure for multiple comparisons (Holm, 1979) . Trends with respect to dose were analyzed using contrasts.
Dose-related trends in the pathology data for animals administered aconiazide were calculated with the Cochran-Armitage test. A Poly-3 test, which corrects for animals dying before the end of the study (Bailer and Portier, 1988) , was used for isoniazid-treated rats. The proportion of pathological lesions in each dose group treated with aconiazide was compared to the proportion of the same lesion in the control group using Fisher's Exact test for one-sided comparisons. The Poly-3 test was used with rats administered isoniazid. All p values were adjusted using Holm's procedure (Holm, 1979) , and all tests were one-sided.
Clinical chemistry and hematological data were analyzed by a one-way analysis of variance model. Contrasts were used to make comparisons to the controls, and a Bonferroni correction was applied. A linear contrast was used to test for doserelated trends.
RESULTS

Morbidity and Mortality
With the exception of one male rat in the 400 mg/kg body wt aconiazide dose group, all rats administered aconiazide survived the entire treatment period. There were no deaths in the 46 or 91 mg/kg body wt isoniazid groups; however, in the 183 mg/kg body wt isoniazid group, there was a significant increase in mortality and morbidity compared to controls, with eight of the male rats (p < 0.001) and six of the female rats (p < 0.01) being removed prior to the end of the study.
Body and Liver Weight Changes
Aconiazide treatment caused a significant dose-related decrease (p < 0.0001 for male rats and p < 0.0009 for female rats) in body weight in both sexes. Compared to control rats, there was a significant decrease (p < 0.05) in body weight after 17 weeks of dosing in the 100 mg/kg body wt male rat group, after 9 weeks in the 200 mg/kg body wt male rat group, and after 5 weeks in the 400 mg/kg body wt group ( Fig. 2A) . In female rats, only the 400 mg/kg body wt aconiazide group differed significantly in weight from the control group, and this occurred after 4 weeks of treatment ( Fig. 2B ).
There was a significant (p < 0.001) dose effect in body weight in both sexes administered isoniazid. The decrease in body weight became significant (p < 0.05) after 8 weeks of dosing in the 91 mg/kg body wt male rat group and after 4 weeks in the 183 mg/kg body wt male rat group (Fig. 2C ). In female rats, only the 183 mg/kg body wt group differed significantly in weight from the control group, with this occurring following 12 weeks of treatment ( Fig. 2D ). Aconiazide treatment caused a dose-related increase in liver weight in female rats (p < 0.006) and a decrease in male rats (p < 0.01); however, none of the values differed significantly from the control rats. In male rats, the administration of isoniazid resulted in a significant dose-related decrease in liver weight (p < 0.001); furthermore, the liver weights in the 183 mg/kg body wt male rats were significantly less than each of the other groups (p < 0.001). In female rats, none of the values differed significantly from the control rats.
Pathology
Twenty-eight of the rats treated with aconiazide were found to have a single liver nodule that was visible grossly. Three additional rats had two grossly visible liver nodules. Microscopically, 27 of the nodules were diagnosed as nodular hepatocellular hyperplasia. The remaining seven liver nodules were diagnosed as hepatodiaphragmatic nodules, a congenital lesion resulting from a malformation of the tendinous of the diaphragm that permits protrusion of the liver into the defect. Female rats a Male and female F344 rats were treated daily by gavage for 182 days with the aconiazide dose indicated in mg/kg body wt. One day following the last dose, the animals were sacrificed for necropsy and histopathology.
Incidence. Severity: the seventy grades were 1-4, with 1, minimal; 2, mild; 3, moderate; and 4, marked.
Significantly different (p < 0.01 after Bonferroni adjustment for multiple comparisons) from controls.
As shown in Table 1 , the hyperplastic nodules were distributed in male rats in a dose-related manner (p < 0.007). Likewise, a dose-related induction (p < 0.003) of hyperplastic nodules was detected in female rats administered aconiazide. With one exception, the nodular hyperplasia was observed only in the left lobe of the liver. They presented as single nodules protruding from the edge of the liver adjacent to the hilus and, microscopically, consisted of normal hepatocytes. The lobular architecture was minimally disorganized and the adjacent hepatic parenchyma was not compressed. Staining for PCNA, a marker for cell proliferation, revealed a similar or slightly increased number of proliferating hepatocytes in the nodule compared to the adjacent parenchyma.
In addition to the grossly visible liver nodules, cytoplasmic alterations were noted microscopically in rats administered aconiazide (Table 1 ). In female rats, this was characterized as diffuse cytoplasmic vacuolization, and osmium tetroxide, a stain for fat, revealed fat in many of the vacuoles. The lesion showed a pronounced dose-related effect (p < 0.000001). In male rats, the cytoplasmic alteration was not vacuolar and was termed diffuse cytoplasmic alteration. This lesion consisted of slight enlargement of hepatocytes, as a result of increased cytoplasmic hypertrophy. The affected cytoplasm stained with increased eosinophilia and presented a ground glass appearance. Although the degree of severity of the lesion appeared minimal, sinusoids were narrowed by the diffuse enlargement of the hepatocytes. This lesion was dose-related (p < 0.000002).
Daily aconiazide administration caused a dose-related (p < 0.000003 in male rats and p < 0.013 in female rats) sciatic nerve lesion, which was characterized as multifocal axonal degeneration (Table 1) . Schwann cell hyperplasia of the sciatic nerve was also noted in one of the I00 mg/kg body wt male rats and eight of the manner (p < 0.00003).
Twenty-nine of the rats treated daily with isoniazid were found to have a single liver nodule that was visible grossly. Two additional rats had two grossly visible liver nodules. Microscopically, 22 of the nodules were diagnosed as nodular hepatocellular hyperplasia ( Table 2) , which occurred in the left lobe of the liver, adjacent to the hilus. The lobular architecture of the nodules was similar to that of the unaffected adjacent parenchyma, and staining for PCNA was not more pronounced compared to the adjacent normal parenchyma. The incidence of this lesion was marginally related (p < 0.030) to dose in female rats. Nine of the remaining liver nodules were diagnosed as hepatodiaphragmatic nodules, and two were not confirmed upon microscopic examination.
Centrilobular hepatic necrosis or its presumed precursor lesion, centrilobular hepatic cytoplasmic alteration, was detected in seven of the eight male rats from the 183 mg/kg body wt isoniazid group (Table 2 ) that were removed due to death or morbidity prior to the scheduled end of the study. The combined incidence of both lesions was significantly elevated (p < 0.001) compared to controls, as was the incidence of the centrilobular cytoplasmic alteration (p < 0.027); the incidence of centrilobular necrosis was only marginally significant (p < 0.063). In the three rats with centrilobular hepatic necrosis, the lesion appeared to be the cause of death. Neither centrilobular hepatic necrosis nor centrilobular hepatic cytoplasmic alteration was found in any of the six female rats that were removed before and six female rats from the 183 rng/kg body wt isoniazid group did not survive the entire 182-day treatment period.
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the terminal sacrifice; however, one female rat from the 183 mg/kg body wt isoniazid group did have a severe centrilobular fatty change (Table 2) .
Daily isoniazid administration caused a dose-related (p < 0.00001 in male rats and female rats) multifocal axonal sciatic nerve degeneration of minimal severity (Table 2) , with the incidence being significantly greater (p < 0.OOOOl) than controls in the 91 mgkg body wt group in male rats and in the 183 mg/kg body wt group in female rats. Schwann cell hyperplasia of the sciatic nerve also increased in a dose-related manner (p < 0.00001) in male rats, with the incidence in the 183 mg/kg body wt group being significantly greater (p < 0.00001) than that observed in the controls.
Clinical Chemistry and Hematology
Aconiazide treatment caused statistically significant (p < 0.01), dose-related linear increases in blood urea nitrogen and creatinine in both sexes (Table 3) . 
Male and female F344 rats were treated daily by gavage for 182 days with 0, 100,200, or 400 mg/kg body wt of aconiazide or an equimolar amount of isoniazid. Arrows indicate the statistically significant, dose-related linear increase ( t ) or decrease ( ) change relative to the control rats. Double arrows indicate a greater than twofold increase ( t t ) or decrease ( . 1 J );indicates that the change was not significant. J Am Coll Toxicol, Vol. 14, No. 4, 1995 
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There were also significant (p < 0.001) increases in alanine aminotransferase, alkaline phosphatase, and triglycerides in female rats and cholesterol in male rats.
The administration of aconiazide caused dose-related (p < 0.01) linear decreases in hemoglobin, hematocrit, mean erythrocyte volume, and reticulocytes, and increases in partial thromboplastin time in both sexes (Table 3 ). In female rats, mean erythrocyte hemoglobin and monocytes also showed decreases (p < 0.001), whereas in male rats decreases (p < 0.02) were observed in the erythrocyte count and eosinophiles.
Isoniazid treatment caused statistically significant (p < 0.02), dose-related linear increases in blood urea nitrogen, bilirubin, and albumin, and decreases in alanine aminotransferase and creatinine (Table 3) . Increases (p < 0.05) were also observed in both sexes in reticulocytes and platelets, whereas decreases occurred in hemoglobin, hematocrit, mean erythrocyte volume, and mean erythrocyte hemoglobin (Table 3) .
Plasma Levels of Aconiazide and Isoniazid
In rats treated with aconiazide, the plasma levels of isoniazid were typically 1CL20 times that of aconiazide, and the levels of both compounds were two-to threefold higher in female rats as compared to male rats ( Table 4 ). As a function of dose, a twofold increase in the administered dose of aconiazide typically gave a twofold increase in the plasma levels of both isoniazid and aconiazide ( Table 4 ). As a function of time, the plasma levels of both compounds were relatively con- 15,29,43,71,99, 127,  and 155 . The data are presented as the mean k SE for all determinations at a particular dose.
One sample obtained on day 29 had a very high level of isoniazid and was excluded from the analysis.
One sample obtained on day 127 did not have a detectable level of aconiazide and was excluded from the analysis.
Two samples obtained on day 127 did not have detectable levels of aconiazide and were excluded from the analysis. Samples obtained on day 29 had very low levels of isoniazid and were excluded from the analysis. na, not analyzed. stant in the 100 and 200 mg/kg body wt aconiazide groups (Figs. 3A and 3B) . With the 400 mg/kg body wt aconiazide groups, however, the highest mean levels of isoniazid were detected at 29 days and the values decreased by 70-80% by day 155. In contrast to the isoniazid plasma levels, the plasma levels of aconiazide in the 400 mg/kg body wt aconiazide groups generally increased with time, with the values being two-to fourfold higher at 155 days as compared to 29 days.
In rats administered isoniazid, the plasma levels of isoniazid were similar in both sexes ( Table 4 ). As afunction of dose, a twofold increase in the administered dose of isoniazid gave a twofold increase in the plasma levels of isoniazid ( Table  4 ). As a function of time, the plasma levels of isoniazid tended to increase with repeated dosing, but then decreased at later sampling times (Fig. 3C) . With the 46 mg/kg body wt isoniazid dose, the maximum levels were observed at 127 days; with the other treatments, the maximum values were found at 71 or 99 days. 
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DISCUSSION
Aconiazide and isoniazid caused dose-related changes in animal survival, body weight, and liver weight, induced certain pathological lesions, and resulted in alterations in certain hematological and clinical chemistry parameters. A comparison of these data, however ( Table 5 ) , suggests that the toxic effects are more pronounced in rats treated with isoniazid than in those treated similarly with equimolar doses of aconiazide. For example, isoniazid treatment caused a significant increase in morbidity and mortality, with 57% of the male rats and 43% of the female rats in the highest dose group being removed before the scheduled end of the experiment. By comparison, aconiazide resulted in only one death during the 6-month experiment. Similarly, although both compounds caused decreases in body weight (Fig. 2) , the effects were greater in the rats administered isoniazid. Likewise, centrilobular necrosis and its presumed precursor lesion, centrilobular cytoplasmic alteration, were only observed in rats administered isoniazid.
In addition to liver pathology, sciatic nerve lesions, including axonal degener- days with 0, 100,200 , or 400 mg/kg body wt of aconiazide or an equimolar amount (0,46,91, or 183 mg/kg body wt) of isoniazid. Unless indicated otherwise, the effect is statistically different than that observed in the control animals and occurred at the highest dose level (i.e., 400 mg/kg body wt of aconiazide and 183 mg/kg body wt of isoniazid).
Not significantly different from control group. Significantly different (p = 0.013 for males; p = 0.016 for females) from rats treated with an 340 F. A . BELAND ET AL.
ation and Schwann cell hyperplasia, were induced by both compounds, with the incidence being slightly greater in rats treated with isoniazid. As noted previously , the sciatic nerve lesions may be a result of drug-induced pyridoxine deficiency, which is felt to be the cause of the peripheral neuropathies observed in humans (Davidson and Le, 1992) . This condition can be prevented by pyridoxine supplementation. In an earlier study , bone marrow depletion was detected in male and female rats treated daily for 14 days with aconiazide at 750 or 1,000 mg/kg body wt. This alteration was not found in the current study with either aconiazide or isoniazid. Aconiazide-induced alterations in clinical chemistry parameters were slight, and the values did not differ appreciably from those expected in rats of this age (Wolford et al., 1986) . Likewise, the clinical chemistry changes induced by isoniazid were slight, and, with the exception of the bilirubin concentration, the values did not differ appreciably from those expected. The increase in bilirubin content suggested that isoniazid was causing biliary obstruction; however, because other hepatic enzymes indicative of this response (e.g., alkaline phosphatase) were not elevated, the significance of this increase is not clear.
Although dose-related changes were observed in certain hematology parameters in the rats administered aconiazide, with the exception of partial thromboplastin time, the values were within expected range (Wolford et al., 1986) . In both sexes, the partial thromboplastin time nearly doubled between the control and the 400 mg/kg body wt aconiazide groups, which suggests that aconiazide may interfere with factors involved in the clotting cascade. The hematology parameters in rats treated with isoniazid were within the range expected for rats of this age, with the exception of the platelet count, which increased threefold in the 183 mg/kg body wt group as compared to the other treatment groups. High platelet counts are associated typically with malignancy, inflammation, hemolysis, bleeding, iron deficiency, or a myeloproliferative disorder (Handin, 1985) . None of these conditions was evident in the high-dose animals; thus, the reason for the increase in platelets is not known.
Centrilobular hepatic necrosis, centrilobular hepatic cytoplasmic alteration, and Schwann cell hyperplasia occurred in male, but not female rats treated with isoniazid. The toxicities associated with isoniazid have been attributed to its metabolism to acetyldiazene through a pathway involving acetylation to form acetylisoniazid, hydrolysis to isonicotinic acid and acetylhydrazine, cytochrome P-45katalyzed oxidation to acetyldiazene, and dissociation of the acetyldiazene to give an electrophilic acetyl radical or carbocation (Timbrel1 et al., 1980) . The administration of isoniazid induces primarily cytochrome P-450 IIE1 (Ryan et al., 1985; Park et al., 1993) , a process that is not sex-related, and this is consistent with the observation that plasma levels of isoniazid were similar in both sexes. Nonetheless, there may be sex differences in the acetylation of isoniazid and oxidation of acetylhydrazine that could lead to the increased hepatotoxicity and neurotoxicity, which may not be apparent from the analysis of plasma isoniazid levels. It should be noted, however, that although there were sex-related differences in the incidence of these pathological lesions, overall mortality from isoniazid was similar in both sexes.
In rats administered aconiazide, the plasma levels of its hydrolysis product, isoniazid, were typically 10-20 times that of aconiazide, and the levels of both compounds were two-to threefold higher in female rats as compared to male rats, which may reflect subtle sex-related differences in the metabolism of aconiazide. More importantly, the drug levels in aconiazide-dosed animals were only 5-10% of that found in isoniazid-treated rats. The fact that much higher plasma levels of isoniazid were obtained during isoniazid treatment as compared to when aconiazide was administered suggests that greater amounts of acetyldiazene were formed, with a resultant increase in toxicity. The relatively low plasma levels of aconiazide and isoniazid in animals treated with aconiazide may be a consequence of its carboxymethyoxy moiety. This function will presumably be ionized at physiological pH, which should decrease intestinal absorption of aconiazide as compared to isoniazid (Klaassen and Rozman, 1991) . In addition, aconiazide could form ionic interactions with protonated amine residues on proteins, thus decreasing further the circulating levels of the free drug.
